CYP2C9 and type 2 diabetes mellitus: The majority of Mexican patients with diabetes mellitus type 2 (DMT2) (67.9–85.0%) are prescribed sulphonylureas (SUs), which are metabolized by cytochrome P450 2C9 (abbreviated as CYP2C9).